To hear about similar clinical trials, please enter your email below
Trial Title:
GENomic PROfilation for Therapeutic Purposes in SARComas and Molecular Tumor Board (MTB): Retrospective/Prospective Study in Referral Centers
NCT ID:
NCT06076070
Condition:
Sarcoma
Conditions: Official terms:
Sarcoma
Study type:
Observational [Patient Registry]
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Summary:
Multicenter noninterventional, translational study, retrospective/prospective designed in
order to assess the aptitude to the use of genomic profiling methods for therapeutic
purposes and evaluation by the institutional Molecular Tumor Board (MTB) of sarcoma
patients with metastatic/locally advanced disease that is inoperable with no viable
therapeutic alternatives or with histotypes known to be resistant to available in-label
medical treatments and without already therapeutically validated driver mutations.
Criteria for eligibility:
Study pop:
Multicenter noninterventional, translational study, retrospective/prospective designed in
order to assess the aptitude to the use of genomic profiling methods for therapeutic
purposes and evaluation by the institutional Molecular Tumor Board (MTB) of sarcoma
patients with metastatic/locally advanced disease that is inoperable with no viable
therapeutic alternatives or with histotypes known to be resistant to available in-label
medical treatments and without already therapeutically validated driver mutations.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Sarcoma patients of any age (inclusion of centers pediatric)
- Patients with any histotype of soft tissue sarcomas and bone
- Patients at any stage of the treatment pathway for disease that is localized or
metastatic/inoperable
- Availability of follow-up data
- Written informed consent (prospective part/patients in follow-up)
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
"Regina Elena" National Cancer Institute
Address:
City:
Rome
Zip:
00144
Country:
Italy
Status:
Recruiting
Contact:
Last name:
Virginia Ferraresi, MD
Phone:
0652665144
Email:
virginia.ferraresi@ifo.it
Start date:
May 25, 2022
Completion date:
May 25, 2024
Lead sponsor:
Agency:
Regina Elena Cancer Institute
Agency class:
Other
Collaborator:
Agency:
Candiolo Cancer Institute - IRCCS
Agency class:
Other
Collaborator:
Agency:
Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale
Agency class:
Other
Collaborator:
Agency:
Istituto Oncologico Veneto IRCCS
Agency class:
Other
Collaborator:
Agency:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Agency class:
Other
Collaborator:
Agency:
Istituto Ortopedico Rizzoli
Agency class:
Other
Collaborator:
Agency:
Ospedale Pediatrico Bambin Gesù
Agency class:
Other
Collaborator:
Agency:
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Agency class:
Other
Collaborator:
Agency:
Istituti Tumori Giovanni Paolo II
Agency class:
Other
Collaborator:
Agency:
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Agency class:
Other
Source:
Regina Elena Cancer Institute
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06076070
